123ArticleOnline Logo
Welcome to 123ArticleOnline.com!
ALL >> General >> View Article

Roots Analysis Has Done A Detailed Study On Tcr-based Therapies, Covering Key Aspects Of The Industry’s Evolution And Identifying Potential Future Gro

Profile Picture
By Author: kylie
Total Articles: 81
Comment this article
Facebook ShareTwitter ShareGoogle+ ShareTwitter Share

Key Market Insights
 More than 100 industry and non-industry players are currently evaluating the potential of over 190 TCR-based immunotherapies for the treatment of various oncological and non-oncological disorders
 More than 90% of the therapy candidates, which are being developed to target a wide range of disease indications are autologous in nature; NY-ESO-1 and MAGE have emerged as the most popular target antigens
 In the last 10 years, close to 110 clinical trials have been registered across different geographies for the evaluation of TCR-based therapies; extensive efforts are underway to improve the successive generations of such therapies
 Close to 60 scientists from renowned universities are presently involved in the clinical development of TCR-based therapies; majority of these KOLs are primarily based in the US and China
 Close to 200 players claim to have the required capabilities to manufacture different types of cell therapies; such firms also offer a wide range of services across different stages of product development
 A growing interest in this field is ...
... reflected from the increase in the partnership activity, involving both international and indigenous stakeholders; majority of such deals were signed between players based in North America
 Several investors, having realized the opportunity within this upcoming segment of T-cell immunotherapy, have invested USD 11 billion, across 140 instances, since 2007
 More than 75 patents have been filed / granted by various stakeholders in order to protect the intellectual property generated within this field
 With a growing focus on the development pipeline and encouraging clinical results, the TCR Therapy market is anticipated to witness an annualized growth rate of 51%, in the next decade

Table of Contents

1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Key Questions Answered
1.6. Chapter Outlines


3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action Active Immunotherapy Passive Immunotherapy
3.5.2. By Type of Target
3.5.3. By Approach Activation and Suppression Immunotherapy
3.5.4. By Product Class Monoclonal Antibodies Bispecific Antibodies Cytokines Oncolytic Virus Therapy Therapeutic Cancer Vaccines Cell-based Therapies
3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods Retroviral Vectors Lentiviral Vectors Non-viral Transfection Methods
3.7. T-Cell Receptor (TCR)-based Cell Therapy
3.7.1. Development History
3.7.2. Anatomical Layout of TCR
3.7.3. Development of TCR Therapy
3.7.4. Differences between CAR-T and TCR-based Therapies
3.8. Concluding Remarks

4.1. Chapter Overview
4.2. TCR-based Therapies: Overall Market Landscape
4.2.1. Analysis by Type of Developer
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Phase of Development and Therapeutic Area
4.2.5. Analysis by Key Target Indication
4.2.6. Analysis by Key Target Antigen
4.2.7. Analysis by Source of T-Cells
4.2.8. Analysis by Route of Administration
4.2.9. Analysis by Phase of Development and Route of Administration
4.2.10. Analysis by Dosing Frequency
4.2.11. Analysis by Target Patient Segment
4.2.12. Analysis by Type of Therapy
4.2.13. Analysis by Phase of Development and Type of Therapy
4.2.14. Most Active Industry Players: Analysis by Number of TCR-based Therapies
4.2.15. Most Active Non-Industry Players: Analysis by Number of TCR-based Therapies

4.3. TCR-based Therapies: Overall Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters

5.1. Chapter Overview
5.2. Competitive Analysis: Popular Target Antigens of TCR-based Therapies
5.2.1. Popular Targets Related to Hematological Malignancies
5.2.2. Popular Targets Related to Solid Tumors

6.1. Chapter Overview
6.2. Scope and Methodology
6.3. TCR-based Therapies: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
6.3.3. Analysis by Trial Status
6.3.4. Analysis by Trial Registration Year and Trial Status
6.3.5. Analysis by Trial Phase
6.3.6. Analysis of Enrolled Patient Population by Trial Phase
6.3.7. Analysis by Target Patient Segment
6.3.8. Analysis by Type of Sponsor / Collaborator
6.3.9. Analysis by Study Design
6.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
6.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
6.3.12. Word Cloud Representation Analysis: Emerging Focus Areas
6.3.13. Analysis of Clinical Trials by Geography
6.3.14. Analysis of Enrolled Patient Population by Geography

7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. TCR-based Therapies: Key Opinion Leaders
7.4.1. Analysis by Type of Organization
7.4.2. Analysis by Affiliated Organization
7.4.3. Analysis by Qualification
7.4.4. Analysis by Geographical Location of KOLs
7.4.5. KOL Activeness versus KOL Strength
7.4.6. Most Prominent KOLs: Analysis by RA score
7.4.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

8.1. Chapter Overview
8.2. Kimmtrak® / IMCgp100 / Tebentafusp (Immunocore)
8.2.1. Therapy Overview
8.2.2. Clinical Trial Information
8.2.3. Clinical Trial Endpoints
8.2.4. Clinical Trial Results
8.2.5. Estimated Sales Revenues

8.3. GSK3377794 / NY-ESO-1C259 T-cells / Letetresgene Autoleucel (GlaxoSmithKline)
8.4. ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics)
8.5. JTCR016 (Juno Therapeutics)
8.6. TBI-1301 (Takara Bio)
8.7. MDG1011 (Medigene)

9.1. Chapter Overview
9.2. Partnership Models
9.3. TCR-based Therapies: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year of Partnership and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Most Popular Products: Analysis by Number of Partnerships
9.3.6. Most Active Industry Players: Analysis by Number of Partnerships
9.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships

9.3.8. Analysis by Geography Intercontinental and Intracontinental Deals International and Local Deals

10.1. Chapter Overview
10.2. Types of Funding
10.3. TCR-based Therapies: Funding and Investment Analysis
10.3.1. Analysis of Instances by Year
10.3.2. Analysis of Amount Invested by Year
10.3.3. Analysis by Type of Funding
10.3.4. Analysis by Type of Investor
10.3.5. Most Active Players: Analysis by Number of Instances
10.3.6. Most Active Investors: Analysis by Amount Invested
10.3.7. Analysis of Amount Invested by Geography
10.3.8. Most Active Investors: Analysis by Number of Funding Instances

11.1. Chapter Overview
11.2. Scope and Methodology
11.3. TCR-based Therapies: Patent Analysis
11.3.1. Analysis by Patent Publication Year
11.3.2. Analysis By Patent Application Year
11.3.3. Analysis by Geography
11.3.4. Analysis by Type of Player
11.3.5. Analysis by CPC Symbols
11.3.6. Analysis by Key Focus Area
11.3.7. Leading Player: Analysis by Number of Patents
11.3.8. TCR-based Therapies: Patent Benchmarking
11.3.9. Analysis By Patent Characteristics
11.3.10. TCR-based Cell Therapies: Patent Valuation

12.1. Chapter Overview
12.2. Overview of Cell Therapy Manufacturing
12.3. Cell Therapy Manufacturing Models
12.3.1. Centralized Manufacturing Model
12.3.2. Decentralized Manufacturing Model
12.4. Scalability of Cell Therapy Manufacturing Processes
12.4.1. Scale-Up
12.4.2. Scale-Out
12.5. Types of Cell Therapy Manufacturers
12.6. Key Challenges Related to Manufacturing of Cell Therapies
12.7. Important Factors for Cell Therapy Manufacturing
12.7.1. Characterization
12.7.2. Cost of Goods
12.8. Automation of Cell Therapy Manufacturing Processes
12.9. Cell Therapy Manufacturing Supply Chain
12.10. Comparison of Player Having In-House Capabilities and Contract Manufacturers
12.11. Regulatory Landscape
12.12. Future Perspectives

13.1. Chapter Overview
13.2. Factors Contributing to the High Price of Cell / Gene Therapies
13.3. Pricing Models for T-Cell Immunotherapies
13.3.1. Based on Associated Costs
13.3.2. Based on Availability of Competing Products
13.3.3. Based on Patient Segment
13.3.4. Based on Opinions of Industry Experts
13.4. Reimbursement related Considerations for T-cell Immunotherapies
13.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapies

14.1. Chapter Overview
14.2. Scope and Limitations
14.3. Key Assumptions and Forecast Methodology

14.4. Global TCR-based Therapies Market, 2022-2035
14.4.1. TCR-based Therapies Market: Analysis by Target Indication
14.4.2. TCR-based Therapies Market: Analysis by Target Antigen
14.4.3. TCR-based Therapies Market: Analysis by Key Players
14.4.4. TCR-based Therapies Market: Distribution by Geography

14.4.5. Product Wise Sales Forecast Kimmtrak® (IMCgp100 / Tebentafusp) (Immunocore) Sales Forecast (USD Million) Net Present Value (USD Million) Value Creation Analysis GSK3377794 (GlaxoSmithKline) YT-E001 (China Immunotech) ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics) EBV-specific TCR-T cell with Anti-PD1 Aauto-secreted Element (TCRCure Biopharma) NTLA-5001 (Intellia Therapeutics) TBI-1301 (Takara Bio) LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology) FH-MCVA2TCR (TCRCure Biopharma)

15.1. Chapter Overview
15.2. Channels Used for Promotional Campaigns
15.3. Kimmtrak: Promotional Analysis
15.3.1. Drug Overview
15.3.2. Product Website Analysis Message for Healthcare Professionals Message for Patients Informative Downloads
15.3.3. Patient Support Services

16.1. Chapter Overview
16.2. Adaptimmune Therapeutics
16.3. Alaunos Therapeutics
16.4. Company Profiles
16.5. Bristol Myers Squibb
16.6. Cellular Biomedicine Group
16.7. Gilead Sciences
16.8. Cellular Biomedicine Group
16.9. GlaxoSmithKline
16.10. Immatics
16.11. Immunocore
16.12. Lion TCR
16.13. Takara Bio
16.14. Zelluna immunotherapy


18.1. Chapter Overview
18.2. Celyad
18.2.1. Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncology
18.3. Kite Pharma
18.3.1. Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
18.4. Lion TCR
18.4.1. Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer
18.5. TxCell
18.5.1. Interview Transcript: Miguel Forte, Chief Operating Officer



To view more details on this report, click on the link:

You may also be interested in the following titles:
Pharmaceutical Polymers / Medical Polymers Market

Gene Switch Market

You may also like to learn what our experts are sharing in Roots educational series:
Advancements in Automation of Processes: Key Value Driver for Escalated Interest in Cell Therapies Manufacturing Domain

CAR-T Cell Therapies: Addressing Key Unmet Needs Across Various Oncological Indications

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091

Total Views: 37Word Count: 1201See All articles From Author

Add Comment

General Articles

1. Forbes: P360 Is Changing How Life Sciences Companies Communicate
Author: Kimberly Gregorio

2. Why Are People Moving Towards Smart Meters Instead Of Traditional Electricity Meters?
Author: Florence

3. Jewelry For Ashes Is Well-known As Funeral Jewelry!
Author: Andrew Wilson

4. Jute Rugs Reveal: Comfort And Style By Chouhan Rugs
Author: Chouhan Rugs

5. Are You Interested In Fintech?
Author: poddarbschool

6. "organic Jaggery Online: Savor The Sweet Goodness At Your Doorstep"
Author: ajax

7. Brisbane Plant Nursery Now Offers Conifers And Grevilla Robusta
Author: James

8. How To Choose The Best Management Institute?
Author: poddarbschool

9. System Defined Exceptions Types | Salesforce Crm
Author: jayanth

10. Merit Medicine Announces $2m Seed Round To Transform Employer-sponsored Healthcare With Ai-powered Risk Predictions
Author: otis

11. "best Bridal Lehenga Designers In India: Elegance Personified"
Author: ajax

12. "indian Digital Marketing Companies: Unleashing Digital Triumph"
Author: ajax

13. Top 5 Reasons To Get Your Medical Marijuana Card Online In New Jersey Now
Author: MD Ganja

14. Premier Allergy Texas: Your Trusted San Antonio Allergists
Author: Premier Allergy Texas

15. Steel Pipe: A Complete Guide To Installation And Maintenance
Author: Piping Projects US

Login To Account
Login Email:
Forgot Password?
New User?
Sign Up Newsletter
Email Address: